查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134975

全球嗜睡症治療產品線分析 - 2026 年（第二季洞察與臨床試驗）

Global Narcolepsy Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

發作性睡病是一種慢性神經系統睡眠障礙，其特徵為白天過度嗜睡、猝倒、睡眠癱瘓、幻覺和夜間睡眠障礙。目前的治療主要集中於緩解症狀，因此亟需能恢復正常睡眠-覺醒節律的療法。近年來，Orexin（下視丘泌素）缺乏症的研究進展為藥物研發帶來了重大變革，多家公司正在開發處於不同臨床開發階段的新型Orexin標靶療法。

市場促進因素

加速開發Orexin促效劑

  • Orexin缺乏被認為是第1型嗜睡症的主要生物學因素，而Orexin受體促效劑是目前正在研發的最有前景的治療藥物之一。製藥公司正不斷擴大研究項目，旨在恢復生理喚醒調節並提供針對特定疾病的治療方法。

加深我們對睡眠神經科學的理解

  • 睡眠生物學和神經學研究的進展正在加深我們對覺醒調節和疾病機制的理解。這些發現使製藥公司能夠開發更具針對性的療法，這些療法有可能比現有的症狀治療更有效。

日益成長的未滿足臨床需求

  • 儘管已有多種治療方法，但許多患者仍飽受白天嗜睡、猝倒和生活品質低落的困擾。這種未被滿足的需求正推動著對差異化療法的投資，以期獲得持續的症狀控制和更佳的長期療效。

罕見疾病支持環境

  • 針對罕見疾病的監管激勵措施、對嗜睡症的認知提高以及對神經科學研究的加大投入，持續推動臨床開發和研發管線的成長。

市場限制因素

臨床開發週期越來越長。

  • 神經系統藥物的研發需要大量的臨床檢驗，這會導致研發週期延長、研究成本飆升以及監管風險增加。

患者數量少

  • 由於發作性睡病仍是一種罕見的神經系統疾病，招募受試者十分困難，這往往導致臨床試驗週期延長。此外，受試者數量少也增加了研發的複雜性。

在競爭激烈的發展環境中所面臨的挑戰

  • 研發公司必須證明其產品在臨床上比現有的性喚起療法有顯著的改善，同時保持良好的安全性，這帶來了巨大的科學和監管障礙。

管道和技術方面的見解

  • 全球嗜睡症治療藥物研發管線可依研發階段、分子類型、給藥途徑、作用機轉、候選藥物及地區分類。
  • 從研發階段來看，此研發管線涵蓋藥物發現、臨床前研究、I期臨床試驗、II期臨床試驗、III期臨床試驗、監理申報等項目。藥物發現和臨床前研究佔據了研發管線的大部分，因為Orexin生物學的進展不斷催生出新的治療機會。隨著研發人員檢驗新的作用機制，I期和II期臨床試驗正在迅速擴展，但進入III期臨床試驗的候選藥物相對較少。
  • 從分子類型來看，研發管線包括小分子化合物、胜肽療法、Orexin促效劑、生物製藥和基因療法。小分子化合物在研發中佔據主導地位，因為它們可以口服給藥，並且能夠有效滲透到中樞神經系統，從而支持疾病的長期管理。Orexin促效劑仍然是成長最快的類別，因為它們可以直接靶向疾病的生物機制。
  • 從給藥途徑來看，目前正在臨床實驗的療法包括口服、鼻腔、皮下和靜脈注射注射製劑。口服療法因其在慢性治療中的便利性而仍是主要方法，但由於鼻腔給藥能夠快速將藥物輸送到神經系統，人們對鼻腔給藥的興趣也日益成長。
  • 就作用機製而言，正在研發的候選藥物包括Orexin受體促效劑、組織胺通路調變器、多巴胺-去甲腎上腺素再回收抑制劑、單胺能調變器、覺醒增強劑、神經傳導物質調變器以及基於新型機制的療法。Orexin受體促效劑是目前最重要的創新領域，因為它們直接針對與第1型嗜睡症相關的下視丘泌素缺乏症。
  • 我們的主要在臨床實驗藥物候選物包括 TAK-861、TAK-360、ORX750、ALKS 2680、AXS-12（瑞波西汀）、ACT-709478、馬吲哚緩釋片，以及其他目前正在進行臨床開發的在研藥物。

管道趨勢

  • 嗜睡症的治療方法不斷發展，朝著基於作用機制的創新方向發展。

主要趨勢如下：

  • Orexin受體促效劑的研發正在迅速擴展。
  • 加大對疾病修正治療的投資。
  • 擴大I期及II期臨床試驗項目。
  • 長效治療藥物的研發。
  • 加強對精準神經病學的關注。
  • 推廣First-in-Class的治療方法。
  • 人們越來越關注如何提高患者的長期生活品質。

區域趨勢

  • 北美在嗜睡症治療藥物研發方面處於全球領先地位，這得益於其先進的睡眠醫學專業知識、對生物技術的大力投資、有利的監管支持以及完善的臨床試驗基礎設施。該地區在Orexin標靶藥物的研發方面也持續處於領先地位。
  • 歐洲透過合作研究、擴大臨床開發計畫以及支持罕見神經系統疾病創新的法律規範，不斷鞏固其在神經科學領域的地位。
  • 在亞太地區，主要市場生物技術能力、臨床研究基礎設施和醫療保健投資的持續擴張，正在推動更多企業進入嗜睡症治療藥物的研發領域。
  • 新興市場正透過國際研究合作、多中心臨床試驗以及擴大神經學研究能力做出貢獻。

競爭格局

  • 全球嗜睡症治療藥物研發管線包括製藥公司、生技公司、學術研究機構和神經科學專家，他們正在開發下一代睡眠障礙藥物。
  • 領先企業持續投資於Orexin受體促效劑、興奮劑、組織胺通路調變器和新型神經系統療法。策略聯盟、授權協議、臨床夥伴關係和監管合作對於加速產品線開發和商業化仍然至關重要。主要參與者包括武田藥品工業株式會社、Alkermes、Axome Therapeutics、Centessa Pharmaceuticals 和 Idolsia。

未來展望

  • 嗜睡症治療的未來發展將取決於Orexin生物學、精準神經科學以及基於機制的治療創新的持續進展。Orexin受體促效劑可望繼續成為研發的重點，因為它們不僅能夠緩解症狀，還可能恢復生理性的睡眠-覺醒調節。
  • 隨著睡眠神經科學的不斷進步、罕見疾病監管支持以及中期臨床試驗的穩步進展，我們預計到 2035 年，相關研發管線將得到加強，治療選擇也將擴大。

結論

  • 《全球發作性睡病治療管線分析》重點介紹了快速發展的研發趨勢，著重於Orexin標靶療法、精準神經科學和緩解疾病創新。儘管漫長的臨床開發週期、較小的患者群體以及監管方面的挑戰仍然是重大障礙，但睡眠神經科學和靶向藥物研發的持續進步有望徹底改變發作性睡病的治療現狀，同時為製藥公司、生物技術公司、研究人員和投資者創造巨大的機會。

本報告的主要益處

  • 全球嗜睡症治療開發平臺的全面分析。
  • 對處於臨床開發各階段的在臨床實驗藥物進行詳細評估。
  • 深入了解新的作用機轉、臨床進展和未來治療機會。
  • 對產品線策略、創新趨勢和商業化潛力進行競爭分析。
  • 這將成為製藥公司、生技公司、投資者、研究人員、顧問和醫療保健機構的寶貴資訊來源。

公司對我們報告的使用

  • 產品線基準分析、臨床開發規劃、競爭情報分析、許可和合作評估、投資分析、投資組合最佳化、監管策略制定、商業化規劃和長期策略決策。

調查範圍

  • 歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期為 2026 年至 2035 年。
  • 全球嗜睡症治療藥物研發管線進行全面分析，依研發階段、分子類型、給藥途徑、作用機轉、候選藥物及地區細分。
  • 評估產品線成熟度、臨床開發進展、臨床實驗中的治療方法、監管環境和商業化機會。
  • 對策略聯盟、許可活動、競爭定位、創新趨勢和未來發展策略進行評估。
  • 對Orexin受體促效劑、組織胺通路調變器、多巴胺-去甲腎上腺素再回收抑制劑、單胺能調變器、喚醒增強劑、神經傳導物質調變器、新型作用機制以及到 2035 年的新興候選藥物進行分析。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：嗜睡症發展過程的動態

  • 促進因素
  • 抑制因子
  • 正在醞釀中的商業機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Takeda Pharmaceutical Company
    • Alkermes
    • Axsome Therapeutics
    • Centessa Pharmaceuticals
    • Idorsia
  • 管線分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • 1型嗜睡症
    • 2型嗜睡症
  • 研發管線分析：依臨床試驗狀態分類
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前已暫停招募參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 贊助商和合作研究者分析
  • 近期和未來管道趨勢
    • 近期啟動的臨床試驗
    • 目前正在招募參與者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗即將完成
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Takeda Pharmaceutical Company
  • Alkermes
  • Axsome Therapeutics
  • Centessa Pharmaceuticals
  • Idorsia

第7章 圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008978

Narcolepsy is a chronic neurological sleep disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations, and disrupted nighttime sleep. Current treatment options primarily provide symptomatic relief, leaving substantial unmet medical need for therapies capable of restoring normal sleep-wake regulation. Recent discoveries surrounding orexin (hypocretin) deficiency have transformed drug development, with multiple companies advancing novel orexin-targeted therapies across different stages of clinical development.

Market Drivers

Accelerating Orexin Agonist Development

  • Orexin deficiency is recognized as the primary biological driver of Narcolepsy Type 1, making orexin receptor agonists one of the most promising therapeutic classes under development. Drug developers continue expanding research programs designed to restore physiological wakefulness regulation and provide disease-targeted treatment.

Growing Understanding of Sleep Neuroscience

  • Advances in sleep biology and neurological research have improved understanding of wakefulness regulation and disease mechanisms. These discoveries are enabling pharmaceutical companies to develop more targeted therapies with the potential to improve efficacy beyond existing symptomatic treatments.

Rising Unmet Clinical Need

  • Many patients continue to experience excessive daytime sleepiness, cataplexy, and impaired quality of life despite currently available therapies. This unmet need is encouraging investment in differentiated treatments capable of delivering sustained symptom control and improved long-term outcomes.

Supportive Rare Disease Environment

  • Regulatory incentives for orphan diseases, increasing awareness of narcolepsy, and growing investment in neuroscience research continue supporting clinical development and pipeline expansion.

Market Restraints

Long Clinical Development Timelines

  • Neurological drug development requires extensive clinical validation, resulting in lengthy development timelines, high research costs, and increased regulatory risk.

Small Patient Population

  • Narcolepsy remains a rare neurological disorder, making patient recruitment challenging and often extending clinical trial duration. Smaller study populations can also increase development complexity.

Competitive Development Challenges

  • Developers must demonstrate meaningful clinical improvements over established wake-promoting therapies while maintaining favorable safety profiles, creating significant scientific and regulatory hurdles.

Pipeline and Technology Insights

  • The global narcolepsy drug pipeline can be segmented by development stage, molecule type, route of administration, mechanism of action, drug candidate, and geography.
  • By development stage, the pipeline includes discovery, preclinical, Phase I, Phase II, Phase III, and registration-stage programs. Discovery and preclinical programs account for a significant proportion of pipeline activity because advances in orexin biology continue generating new therapeutic opportunities. Phase I and Phase II studies are expanding rapidly as developers validate novel mechanisms, while relatively few candidates have progressed into Phase III.
  • By molecule type, the pipeline consists of small molecules, peptide therapies, orexin agonists, biologics, and gene-based therapies. Small molecules dominate development because oral administration and effective central nervous system penetration support long-term disease management. Orexin agonists remain the fastest-growing category due to their ability to directly target disease biology.
  • By route of administration, investigational therapies include oral, intranasal, subcutaneous, and intravenous formulations. Oral therapies continue to dominate because they support convenient chronic treatment, while intranasal delivery is gaining interest for rapid neurological drug delivery.
  • By mechanism of action, pipeline candidates include orexin receptor agonists, histamine pathway modulators, dopamine-norepinephrine reuptake inhibitors, monoaminergic modulators, wakefulness-promoting agents, neurotransmitter modulators, and novel mechanistic approaches. Orexin receptor agonists represent the most significant area of innovation because they directly address hypocretin deficiency associated with Narcolepsy Type 1.
  • Major investigational drug candidates include TAK-861, TAK-360, ORX750, ALKS 2680, AXS-12 (Reboxetine), ACT-709478, Mazindol ER, and several additional emerging pipeline candidates currently progressing through clinical development.

Pipeline Trends

  • The narcolepsy drug development landscape continues to evolve toward mechanism-based innovation.

Key trends include:

  • Rapid expansion of orexin receptor agonist development.
  • Increasing investment in disease-modifying therapies.
  • Growth in Phase I and Phase II clinical programs.
  • Development of long-acting treatment formulations.
  • Greater emphasis on precision neurological medicine.
  • Expansion of first-in-class therapeutic approaches.
  • Growing focus on improving long-term patient quality of life.

Regional Insights

  • North America leads global narcolepsy drug pipeline activity because of advanced sleep medicine expertise, strong biotechnology investment, favorable regulatory support, and well-developed clinical trial infrastructure. The region remains at the forefront of orexin-targeted drug development.
  • Europe continues to strengthen its position through collaborative neuroscience research, expanding clinical development programs, and supportive regulatory frameworks that encourage innovation in rare neurological diseases.
  • Asia-Pacific is experiencing increasing participation in narcolepsy drug development as biotechnology capabilities, clinical research infrastructure, and healthcare investment continue expanding across major regional markets.
  • Emerging markets are contributing through international research collaborations, multicenter clinical trials, and expanding neurological research capabilities.

Competitive Landscape

  • The global narcolepsy drug pipeline includes pharmaceutical companies, biotechnology firms, academic research organizations, and neuroscience specialists developing next-generation sleep disorder therapies.
  • Leading organizations continue investing in orexin receptor agonists, wakefulness-promoting agents, histamine pathway modulators, and novel neurological therapies. Strategic collaborations, licensing agreements, clinical partnerships, and regulatory engagement remain essential for accelerating pipeline progression and commercialization. Key companies include Takeda Pharmaceutical Company Limited, Alkermes plc, Axsome Therapeutics Inc., Centessa Pharmaceuticals plc, and Idorsia Ltd.

Future Outlook

  • The future of the narcolepsy drug pipeline will be shaped by continued advances in orexin biology, precision neuroscience, and mechanism-based therapeutic innovation. Orexin receptor agonists are expected to remain the primary focus of development because of their potential to restore physiological sleep-wake regulation rather than simply treating symptoms.
  • Continued progress in sleep neuroscience, regulatory support for rare diseases, and successful advancement of mid-stage clinical candidates are expected to strengthen the pipeline and improve treatment options through 2035.

Conclusion

  • The Global Narcolepsy Drug Pipeline Analysis highlights a rapidly evolving development landscape centered on orexin-targeted therapies, precision neurology, and disease-modifying innovation. Although long clinical development timelines, small patient populations, and regulatory challenges remain significant barriers, ongoing advances in sleep neuroscience and targeted drug development are expected to transform narcolepsy treatment while creating substantial opportunities for pharmaceutical companies, biotechnology firms, researchers, and investors.

Key Benefits of this Report

  • Comprehensive analysis of the global narcolepsy drug development pipeline.
  • Detailed evaluation of investigational drug candidates across all clinical development stages.
  • Insights into novel mechanisms of action, clinical progress, and future therapeutic opportunities.
  • Competitive assessment of pipeline strategies, innovation trends, and commercialization potential.
  • Valuable resource for pharmaceutical companies, biotechnology firms, investors, researchers, consultants, and healthcare organizations.

What Businesses Use Our Reports For

  • Pipeline benchmarking, clinical development planning, competitive intelligence, licensing and partnership evaluation, investment analysis, portfolio optimization, regulatory strategy development, commercialization planning, and long-term strategic decision-making.

Report Coverage

  • Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global narcolepsy drug pipeline by development stage, molecule type, route of administration, mechanism of action, drug candidate, and geography
  • Evaluation of pipeline maturity, clinical development progress, investigational therapies, regulatory landscape, and commercialization opportunities
  • Assessment of strategic collaborations, licensing activities, competitive positioning, innovation trends, and future development strategies
  • Analysis of orexin receptor agonists, histamine pathway modulators, dopamine-norepinephrine reuptake inhibitors, monoaminergic modulators, wakefulness-promoting agents, neurotransmitter modulators, novel mechanistic approaches, and emerging pipeline candidates through 2035.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. NARCOLEPSY PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Takeda Pharmaceutical Company
    • 5.1.2. Alkermes
    • 5.1.3. Axsome Therapeutics
    • 5.1.4. Centessa Pharmaceuticals
    • 5.1.5. Idorsia
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. Narcolepsy Type 1
    • 5.4.2. Narcolepsy Type 2
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Takeda Pharmaceutical Company
  • 6.2. Alkermes
  • 6.3. Axsome Therapeutics
  • 6.4. Centessa Pharmaceuticals
  • 6.5. Idorsia

7. LIST OF TABLES

8. LIST OF FIGURES